Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 6, 2012, Pages 891-899

  Vergara, Daniele ^a,b   Bellomo, Claudia ^c   Zhang, Xingcai ^d   Vergaro, Viviana ^c   Tinelli, Andrea ^e   Lorusso, Vito ^e   Rinaldi, Ross ^f   Lvov, Yuri M ^d   Leporatti, Stefano ^c   Maffia, Michele ^a,b  

^a UNIVERSITY OF SALENTO   (Italy)

^b Giovanni Paolo II Hospital   (Italy)

^c NNL Istituto Nanoscienze   (Italy)

^d LOUISIANA TECH UNIVERSITY   (United States)

^e VITO FAZZI HOSPITAL   (Italy)

^f CNR   (Italy)

Author keywords

Lapatinib; Nanocapsules; Ovarian cancer; Paclitaxel; Sonication assisted Layer by Layer

Indexed keywords

CONTROLLED RELEASE; DRUG CONTENT; DRUG-DELIVERY SYSTEMS; GROWTH INHIBITION; IN-VITRO; IN-VIVO; LAPATINIB; LAYER-BY-LAYERS; LOW TOXICITY; MULTIDRUG RESISTANCE; NANO-COLLOIDS; NANOCOLLOID; OVARIAN CANCER CELLS; OVARIAN CANCERS; PACLITAXEL; THERAPEUTIC APPLICATION;

BIOCOMPATIBILITY; BIODEGRADATION; CELL CULTURE; DEPOSITION; DISEASES; POLYELECTROLYTES;

NANOCAPSULES;

ALGINIC ACID; CHITOSAN; LAPATINIB; NANOCAPSULE; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; OVARY CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; COLLOIDS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NANOCAPSULES; OVARIAN NEOPLASMS; PACLITAXEL; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84864083044     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.10.014     Document Type: Article

References (48)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
2. Vasey P.A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003, 89:S23-S28.
3. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327.
4. Sandor V., Fojo T., Bates S.E. Future perspectives for the development of P-glycoprotein modulatore. Drug Resist Updat 1998, 1:190-200.
5. Ferrandina G., Zannoni G.F., Martinelli E., Paglia A., Gallotta V., Mozzetti S., et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006, 12:2774-2779.
6. Szajnik M., Szczepanski M.J., Czystowska M., Elishaev E., Mandapathil M., Nowak-Markwitz E., et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009, 28:4353-4363.
7. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868.
8. Huang L., Ao Q., Zhang Q., Yang X., Xing H., Li F., et al. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J Cancer Res Clin Oncol 2010, 136:447-456.
9. Van Zuylen L., Verweij J., Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001, 19:125-141.
10. Zahr A.S., Pishko M.V. Encapsulation of paclitaxel in macromolecular nanoshells. Biomacromolecules 2007, 8:2004-2010.
11. Li X., Li P., Zhang Y., Zhou Y., Chen X., Huang Y., Liu Y. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res 2010, 27:1498-1511.
12. Ooya T., Lee J., Park K. Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug Chem 2004, 15:1221-1229.
13. Zhao H., Wang J.C., Sun Q.S., Luo C.L., Zhang Q. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 2009, 17:10-18.
14. Lvov Y.M., Pattekari P., Zhang X., Torchilin V. Converting poorly soluble materials into stable aqueous nanocolloids. Langmuir 2011, 27:1212-1217.
15. Pattekari P., Zheng Z., Zhang X., Levchenko T., Torchilin V., Lvov Y. Top-down and bottom-up approach in production aqueous nanocolloids of paclitaxel. Phys Chem Chem Phys 2011, 13:9014-9019.
16. Zhao J., Cui Y., Wang A., Fei J., Yang Y., Junbai L. Side effect reduction of encapsulated hydrocortisone crystals by insulin/alginate shells. Langmuir 2011, 27:1499-1504.
17. Linton K.J. Structure and function of ABC transporters. Physiology (Bethesda) 2007, 22:122-130.
18. Simşek T., Ozbilim G., Gülkesen H., Kaya H., Sargin F., Karaveli S. Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutation S-transferase: can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy. Eur J Gynaecol Oncol 2001, 22:436-438.
19. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11:265-283.
20. Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008, 68:7905-7914.
21. Bantchev G., Lu Z., Lvov Y. Layer-by-layer nanoshell assembly on colloide through simplified washless process. J Nanosci Nanotechnol 2009, 9:396-403.
22. Wang J., Wan W., Sun R., Liu Y., Sun X., Ma D., et al. Reduction of Akt2 expression inhibits chemotaxis signal transduction in human breast cancer cells. Cell Signal 2008, 20:1025-1034.
23. Wang Y., Niu X.L., Qu Y., Wu J., Zhu Y.Q., Sun W.J., et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123.
24. Altomare D.A., Wang H.Q., Skele K.L., De Rienzo A., Klein-Szanto A.J., Godwin A.K., et al. Akt and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to distrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-5857.
25. Yuan Z.Q., Sun M., Feldman R.I., Wang G., Ma X., Jiang C., et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000, 19:2324-2330.
26. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
27. Felt O., Buri P., Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 1998, 24:979-993.
28. Chauhan S.C., Kumar D., Jaggi M. Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res 2009, 2:21.
29. Gao N., Flynn D.C., Zhang Z., Zhong X.S., Walker V., Liu K.J., et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004, 287:281-291.
30. Onyüksel H., Jeon E., Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett 2009, 274:327-330.
31. Qian Y., Corum L., Meng Q., Blenis J., Zheng J.Z., Shi X., et al. PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol 2004, 286:153-163.
32. Amiri A., Noei F., Jeganathan S., Kulkarni G., Pinke D.E., Lee J.M. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene 2007, 26:3027-3040.
33. Vandermoere F., El Yazidi-Belkoura I., Demont Y., Slomianny C., Antol J., Lemoine J., et al. Proteomics exploration reveals that actin is a signaling target of the kinase Akt. Mol Cell Proteomics 2007, 6:114-124.
34. Cenni V., Sirri A., Riccio M., Lattanzi G., Santi S., de Pol A., et al. Targeting of the Akt/PKB kinase to the actin skeleton. Cell Mol Life Sci 2003, 60:2710-2720.
35. van Rheenen J., Condeelis J., Glogauer M. A common cofilin activity cycle in invasive tumor cells and inflammatory cells. J Cell Sci 2009, 122:305-311.
36. Abrams S.L., Steelman L.S., Shelton J.G., Wong E.W., Chappell W.H., Bäsecke J., et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010, 9:1781-1791.
37. Di Leo A., Gomez H.L., Aziz Z., Zvirbule Z., Bines J., Arbushites M.C., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26:5544-5552.
38. Leonard G.D., Polgar O., Bates S.E. ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 2002, 3:1652-1659.
39. Yakirevich E., Sabo E., Naroditsky I., Sova Y., Lavie O., Resnick M.B. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006, 100:152-159.
40. Surowiak P., Materna V., Denkert C., Kaplenko I., Spaczyński M., Dietel M., et al. Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett 2006, 235:272-280.
41. van der Zee A.G., Hollema H., Suurmeijer A.J., Krans M., Sluiter W.J., Willemse P.H., et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995, 13:70-78.
42. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
43. Heath J.R., Davis M.E. Nanotechnology and cancer. Annu Rev Med 2008, 59:251-265.
44. Vergaro V., Scarlino F., Bellomo C., Rinaldi R., Vergara D., Maffia M., et al. Drug-loaded polyelectrolyte microcapsules for sustained targeting of cancer cells. Adv Drug Deliv Rev 2011, 63:847-864.
45. Palamà I.E., Leporatti S., de Luca E., Di Renzo N., Maffia M., Gambacorti-Passerini C., et al. Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. Nanomedicine (Lond) 2010, 5:419-431.
46. Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
47. Wang L., Chen H., Pourgholami M.H., Beretov J., Hao J., Chao H., et al. Anti-MUC1 monoclonal zntibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One 2011, 6:e24405.
48. Yu C., Hu Y., Duan J., Yuan W., Wang C., Xu H., Yang X.D. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to muc1-positive cancer cells in vitro. PLoS One 2011, 6:e24077.